Next report date
Report period
Q1 2024
EPS estimate
0.70EUR
Revenue estimate
8.49 BEUR
2.50EUR
11.22 BEUR
31.15 BEUR
3.11 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Employees (FY)
63.37 K
Founded
1931
FIGI
BBG000DYN870
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NOV is featured.
Frequently Asked Questions
The current price of NOV is 118.28 EUR — it has increased by 0.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVO-NORDISK AS B DK 0,1 stocks are traded under the ticker NOV.
NOVO-NORDISK AS B DK 0,1 is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
NOV stock is 2.26% volatile and has beta coefficient of 1.50. Check out the list of the most volatile stocks — is NOVO-NORDISK AS B DK 0,1 there?
NOV earnings for the last quarter are 0.67 EUR per share, whereas the estimation was 0.64 EUR resulting in a 4.02% surprise. The estimated earnings for the next quarter are 0.61 EUR per share. See more details about NOVO-NORDISK AS B DK 0,1 earnings.
NOVO-NORDISK AS B DK 0,1 revenue for the last quarter amounts to 7.86 B EUR despite the estimated figure of 7.73 B EUR. In the next quarter revenue is expected to reach 8.40 B EUR.
Yes, you can track NOVO-NORDISK AS B DK 0,1 financials in yearly and quarterly reports right on TradingView.
NOV stock has risen by 3.30% compared to the previous week, the month change is a 1.17% fall, over the last year NOVO-NORDISK AS B DK 0,1 has showed a 59.84% increase.
NOV net income for the last quarter is 2.95 B EUR, while the quarter before that showed 3.01 B EUR of net income which accounts for −2.04% change. Track more NOVO-NORDISK AS B DK 0,1 financial stats to get the full picture.
Today NOVO-NORDISK AS B DK 0,1 has the market capitalization of 524.21 B, it has increased by 0.90% over the last week.
NOVO-NORDISK AS B DK 0,1 dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS B DK 0,1 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 63.37 K employees. See our rating of the largest employees — is NOVO-NORDISK AS B DK 0,1 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS B DK 0,1 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS B DK 0,1 stock shows the buy signal. See more of NOVO-NORDISK AS B DK 0,1 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NOVO-NORDISK AS B DK 0,1 future price: according to them, NOV price has a max estimate of 152.92 EUR and a min estimate of 71.00 EUR. Read a more detailed NOVO-NORDISK AS B DK 0,1 forecast: see what analysts think of NOVO-NORDISK AS B DK 0,1 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS B DK 0,1 EBITDA is 15.00 B EUR, and current EBITDA margin is 47.96%. See more stats in NOVO-NORDISK AS B DK 0,1 financial statements.